Economic Burden Of Cancer And Payment Coping Mechanism

Economic Burden Of Cancer And Payment Coping Mechanism

Abstract

The profitable burden of cancer and the stress of payment bear that, health care providers give quality cost-effective care that will dock the stay of cases in the sanitarium and reduce the frequence of visit to health installations. This study delved the profitable burden of cancer cases and payment managing medium in Jos University Teaching Hospital, Plateau State. Four objects and two suppositions were raised to guide the study. Cost- of- illness frame was used to assess the profitable burden of cancer cases and payment managing medium. Across-sectional descriptive check design was used for the study. A sample of 179 cancer cases was drawn successively from an estimated population of 276 that used the sanitarium in one time. Data were anatomized descriptively using frequentness, probabilities, mean and standard divagation. ki- forecourt was used to determine the association between socio- profitable groups and payment managing mechanisms employed by cancer cases and between the cost distributions among different socio- profitable groups. maturity of repliers were ranked among the poorest, the mean yearly total income of the cases is N 65,978.74 104,036.97, mean yearly aggregate charges is N 43,916.28 56,070.33, the mean yearly cases ’ expenditure is N 43,916.28 56,070.33, the mean total periodic loss was N 217,515.19 798,708.95, the mean cases ’ periodic loss as a chance of their mean periodic income is11.3819.13 while as a chance of their mean periodic expenditure was50.06421.98. There was a significant difference in the cost distribution of different socio- profitable groups in terms of yearly cases ’ total income, yearly earnings of persons accompanying cases, cases ’ yearly loss, accompanying persons ’ yearly loss, total yearly loss, cases ’ periodic loss, accompanying persons ’ periodic loss and total periodic loss( P<0.05). Payment managing medium employed by utmost(78.8) of the cases was their own plutocrat( i.e. payment, earnings and/ or savings). There was a significant difference between payment managing medium of cancer cases( espoused plutocrat/ loan, deals of land) and different socio- profitable groups( P<0.05). There’s need for government to intermediate by subsidizing the cost of cancer treatment. There’s need for the conformation of a strong cancer Association in Plateau State so that cancer cases could pool their coffers together as a strong social support to help themselves.

Chapter One

Preface

Background to the Study

Cancer is the alternate leading cause of death and disability in the world followed by heart complaint( Mathers & Lancer, 2006). It’s a major public health issue and represents a significant burden of complaint. Grounded on the most complete and current data available, cancer accounts for one out of every eight deaths annually( Mathers & Lancer, 2006). The prevalence and death rates from cancer remain significantly advanced in the developing world including Nigeria( Boyle & Levin, 2008). It’s responsible for further deaths than all the deaths due to HIV/ AIDS, TB and malaria combined( Okoye, 2010).

Cancer is a group of conditions characterized by unbridled growth and spread of abnormal cells( Global cancer data and numbers, 2011). It affects different corridor of the body and the name of the cancer is given in relation to the part that’s affected. It’s a global complaint that consumes coffers. The cost of cancer treatment encyclopedically is reported to be high. Records have it that developed countries spend further on cancer treatment than developing countries; for illustration in the United States of America, the profitable burden from cancer is tagged at$ 895 billion nearly 20 further than heart conditions risk($ 753 billion)( John & Ross, 2009). The cancers which regard for the largest costs on a global scale, and the topmost burden in advanced nations are; lung, colorectal and bone while by low- income countries, the cancer with the topmost impact are cancer of the mouth and oropharynx, cancer of the cervix, bone and prostate cancer( John & Rose, 2009).